Integrates cardiovascular, renal, and metabolic health — eGFR, BMI, statin use, social determinants. Race no longer a determinant, addressing global equity concerns.

Pharmacotherapy at BP ≥130/80 for CVD, diabetes, CKD, or 10-year CVD risk ≥7.5% via PREVENT. Without these factors: threshold remains ≥140/90.

RDN endorsed for select resistant hypertension patients. Requires multidisciplinary evaluation and shared decision-making. Follows ESC/ESH global endorsement.

Screening for all stage 2 and resistant HTN patients. Significantly underdiagnosed secondary cause worldwide, particularly in LMICs.

Revised guidance for CKD, diabetes, pregnancy, intracerebral hemorrhage, and hypertensive emergencies — applicable across global care settings.